hotspot -WSS

hotspot

author：knowledge 2025-10-02 05:38:51 - browse：348

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Victims of gun violence feel impacts long after bullet wound

WSS

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

The new shift in health care is toward less care

Congress might make insulin pumps more accessible to the blind

Juul documents reveal insider tactics on political lobbying

Ambulance rides for just $100? Advisers want major billing fixes

AMAs digital advisors table RPM coding reform proposal, again

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medical records are filled with copy

MoonLake credibility takes another hit with mid

Apple is now the first public company to be valued at $3 trillion

Congress must protect the remaining independent doctors

Novavax promises a turnaround & Lilly roils the obesity market

Juul documents reveal insider tactics on political lobbying

Anesthesiologist group: stop taking Ozempic before surgery

Medicare solvency divides Republicans at the presidential debate

Moonlake's readout produced a cash windfall. Risks remain

AMAs digital advisors table RPM coding reform proposal, again

entertainment

UCSF medical school apologizes for unethical prisoner experiments

Sanofi CEO defends move to abandon profit guidance, boost research

Congress must protect the remaining independent doctors

FDA approves Recor Medical high blood pressure device

Biotech incubator Curie.Bio graduates its first startup

Why don't Americans have at

knowledge

focus

hotspot

focus